Delamanid

Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids[1].

Product Specifications

CAS Number

[681492-22-8]

Product Name Alternative

OPC-67683

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Delamanid.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 2 mg/mL (ultrasonic)

Smiles

FC(F)(F)OC1=CC=C(OC2CCN(C3=CC=C(OC[C@@]4(C)CN5C(O4)=NC([N+]([O-])=O)=C5)C=C3)CC2)C=C1

Molecular Formula

C25H25F3N4O6

Molecular Weight

534.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Sotgiu G et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015 Mar;13 (3) :305-15.|[2]Xavier AS et al. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5 (3) :222-4|[3]Mallikaarjun S et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60 (10) :5976-85.|[4]Patterson S et al.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016 May 24;5.